Antibody-Drug Conjugate Bioanalytical Solutions
Supporting ADC development with scientifically robust, phase appropriate bioanalysis
Supporting Your ADC Development
Antibody-drug conjugates are an increasingly important therapeutic modality, rising from a niche class to a rapidly expanding global landscape. Their complexity demands deep scientific expertise, sensitive assay design, and reliable analytical execution. Synexa provides comprehensive bioanalytical solutions to support ADC programmes from discovery through to late clinical stages, built on more than 20 years of experience in biomarker and bioanalytical science. Our GLP and GCP-accredited global laboratories deliver high-quality, tailored support for emerging and advanced ADC portfolios.
Our ADC Bioanalysis Services
Pharmacokinetics
- Custom-developed ADC assays
- Total Antibody assays
- Free Payload quantification
- Free Linker quantification
- DAR-aware assay design for enhanced sensitivity and precision
- Over 150 validated biomarker assays using MSD, ELISA and LC-MS/MS
Immunogenicity Profiling
We assess the immune response to ADCs to support safety interpretation, regulatory expectations and phase‑appropriate programme decisions.
- Tiered ADA assays including screening, confirmation and neutralising antibody analysis
- Anti‑ADC ADA assessments across antibody, linker and payload domains
- Functional and ligand‑binding NAb assays suited to in vivo relevance
Mechanisms of Resistance
To support translational insight and early risk identification, Synexa applies advanced in vitro systems to explore resistance development. Capabilities include:
- In vitro resistance modelling using cyclical ADC dosing in cancer cell lines
- Characterisation using MSD, digital PCR, NanoString and lysosomal imaging
- Insights informed by oncology patient networks
Toxicity Evaluation
Our cell-based systems help anticipate potential haematological and off-target risks during development. Services include:
- Ex vivo bone marrow progenitor assays for neutropenia and thrombocytopenia risk assessment
- Long-term cultures with flow cytometric phenotyping and ADC challenge
- Custom models to investigate bystander or off-target toxicity
ADC Bioanalytical Platforms
Our technology platforms are robust, reliable and reputable in the clinical field and provide comprehensive and detailed data readouts for your ADC therapeutic.
Waters T-QS LC-MS/MS
Sciex 6500+
Waters Premier I-Class UPLC
MSD S600
MSD SQ 120
Gyrolab xPlore
FAQ
What are Antibody-Drug Conjugates (ADCs)?
Antibody‑drug conjugates are complex targeted medicines that link a monoclonal antibody to a potent drug payload to deliver treatment directly to specific cells. ADCs are designed to improve precision while reducing harm to healthy tissue
What services does Synexa offer for ADC bioanalysis?
Synexa provides comprehensive, phase‑appropriate bioanalytical and translational services for ADCs, including pharmacokinetics, immunogenicity, resistance analysis and toxicity evaluation.
What technologies does Synexa utilise for ADC bioanalysis?
Synexa utilises advanced UPLC-MS/MS and immunoassay platforms, including Waters I-Class systems, Sciex Triple Quad instruments and MSD, AlphaLISA, ELISA, DELFIA and Gyrolab technologies, to deliver high quality ADC bioanalysis.
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
